Harmony Biosciences Holdings (HRMY) Cash from Operations Growth (3y) (2022 - 2026)
Harmony Biosciences Holdings (HRMY) Cash from Operations Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.27 Bn | 467.47 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 122.18 Bn | 114.93 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.32 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 34.32% |
| 10 | Harmony Biosciences Holdings | 2.08 Bn | 1.56 Bn | 170.88 Mn | -13.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.28% |
| Dec 31, 2025 | 67.85% |
| Sep 30, 2025 | 25.35% |
| Jun 30, 2025 | 32.98% |
| Mar 31, 2025 | 5.61% |
| Dec 31, 2024 | 26.27% |
| Sep 30, 2024 | 32.33% |
| Jun 30, 2024 | 33.11% |
| Mar 31, 2024 | 35.45% |
| Dec 31, 2023 | 96.87% |
| Sep 30, 2023 | 92.56% |
| Jun 30, 2023 | 97.21% |
| Mar 31, 2023 | 53.17% |
| Dec 31, 2022 | 46.00% |